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Available online 8 April 2008The cytoplasmic tail of the HIV transmembrane protein plays an important role in viral infection. In this study
we analyzed the role of retroviral cytoplasmic tails in modulating the cytoskeleton and interfering with virus–
cell fusion. HeLaP4 cells expressing different HIV cytoplasmic tail constructs showed reduced acetylated
tubulin levels whereas the cytoplasmic tail of MLV did not alter microtubule stability indicating a unique
function for the lentiviral cytoplasmic tail. The effect on tubulin is mediated through the membrane proximal
region of the HIV cytoplasmic tail and was independent of membrane localization. Site-directed mutagenesis
identiﬁed threemotifs in the HIV-2 cytoplasmic tail required to effect the reduction in acetylated tubulin. Both
the YxxΦ domain and amino acids 21 to 45 of the HIV-2 cytoplasmic tail need to be present to change the level
of acetylated tubulin in transfected cells. T-cells stably expressing one HIV-2 cytoplasmic tail derived construct
showed also a reduction in acetylated tubulin thus conﬁrming the importance of this effect not only for
HeLaP4 and 293T cells.
Challenge experiments using transiently transfected HeLaP4 cells and T cells stably expressing an HIV
cytoplasmic tail construct revealed both reduced virus–cell fusion and replication of HIV-1NL4.3 compared to
control cells. In the virus–cell fusion assay only virions pseudotyped with either HIV or MLV envelopes
showed reduced fusion efﬁciency, whereas VSV-G pseudotyped virions where not affected by the expression
of HIV derived cytoplasmic tail constructs, indicating that fusion at the plasma but not endosomal membrane
is affected.
Overexpression of human histone-deacetylase 6 (HDAC6) and constitutively active RhoA resulted in a
reduction of acetylated tubulin and reduced virus–cell fusion as signiﬁcant as that observed following
expression of HIV cytoplasmic tail constructs. Inhibition of HDAC6 showed a strong increase in acetylated
tubulin and increase of virus–cell fusion conﬁrming the correlation between post-translational modiﬁcation
of tubulin and virus–cell fusion. These results thus identify tubulin and its post-translational modiﬁcation as a
new cellular target for interference with HIV–cell fusion.
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The long cytoplasmic tail (CT) of the envelope glycoprotein is one of
the unique characteristics of lentiviruses which distinguish them from
other retroviruses. For HIV the gp41 cytoplasmic tail is approximately
150 amino acids long and is highly conserved. It plays an important role
in the incorporation of envelope proteins into virions, during matu-
ration, and modulates viral infection in a cell type speciﬁc manner
(Akari et al., 2000; Celma et al., 2001; Day et al., 2004; Dubay et al.,
1992; Freed and Martin, 1996; Iwatani et al., 2001; Piller et al., 2000;
Wilk, et al., 1992; Wyma et al., 2004). The interaction of gp41 CT with
gagPr55 has been described experimentally (Egan et al., 1996;
Hourioux et al., 2000; Murakami and Freed, 2000; Vincent et al.,ar).
l rights reserved.1999; Wyma, et al., 2000) and recently shown to interfere with en-
velope incorporation (Chan and Chen, 2007).
Although a number of cellular interaction partners for the HIV
cytoplasmic tail have been described (Blancou et al., 2005; Evans et al.,
2002; Ishikawa et al., 1998; Kim et al., 1999; Micoli et al., 2006;
Srinivas et al., 1993; Tencza et al., 1997; Tencza et al., 1995; Yuan et al.,
1995, 2001; Zhang et al., 1999), the effect of expression of these tails in
infected cells on de novo infection or viral superinfection has not been
addressed. Apart from receptor and co-receptor modulation, the role
of the cytoskeleton in HIV infection is of particular interest. The
cytoskeleton is involved in the early events of viral infection,
regulating viral fusion and the movement of viral structures like
the pre-integration complex of HIV (Fackler and Krausslich, 2006;
Pelkmans, 2005). Recently, Valenzuela-Fernandez et al. (Valenzuela-
Fernandez et al., 2005) identiﬁed microtubules and their post-
translational modiﬁcations as a key regulator for viral infection.
Interaction of the outer envelope protein gp120 with CD4 induces an
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resulting in more efﬁcient infection. Reducing the levels of acetylated
tubulin in target cells was shown to reduce virus infection.
In this study we analyzed the effect of target cell expressed
cytoplasmic tails on viral infection and show that HIV-1 and HIV-2
cytoplasmic tails reduce virus–cell fusion by reducing the levels of
acetylated tubulin. Furthermore, the reduction of virus–cell fusion was
shown to be entry route dependent since VSV-G mediated fusion was
not affected by the expression of gp41 cytoplasmic tails in target cells. In
addition, Tcells stably expressing anHIV cytoplasmic tail constructwere
analyzed and showed a reduced level of acetylated tubulin and reduced
HIV-1 replication kinetics. Together these results identify lentiviral
cytoplasmic tails as a new factor involved in reducing virus infection
which, along with gp120 and the accessory proteins Vpu and Nef, may
play a role in the restriction of superinfection (Wildum et al., 2006).
Results
Expression of HIV proviral constructs in HeLaP4 and 293T cells reduces
acetylated tubulin and interferes with virus–cell fusion
Binding of gp120 to target cells via CD4 has been shown to increase
the level of acetylated tubulin and to enhance viral infection whereas
reducing the level of acetylated tubulin through over expression of the
histone-deacetylase HDAC6 resulted in reduced viral infection (Valen-
zuela-Fernandez et al., 2005). These observations promptedus to study
the effect of HIV expression on the levels of acetylated tubulin.
To address this question plasmids encoding full-length HIV-1 were
transfected into HeLaP4 and 293T cells. HIV-1NL4.3, HIV-1NL-A1(CD4−),
and HIV-1NLΔCT were used and changes in acetylated tubulin
quantiﬁed. While HIV-1NL4.3 encodes for an envelope protein that
can bind CD4 and subsequently facilitates infection of HeLaP4 cells,
HIV-1NL-A1(CD4−) is deﬁcient in CD4 binding. HIV-1NLΔCT lacks the
cytoplasmic tail of gp41 but encodes an envelope protein that bindsFig. 1. Changes in acetylation of tubulin and virus–cell fusion upon expression of HIV-1 provi
transfection of HeLaP4 and 293T cells with the full-length constructs HIV-1NL4.3, HIV-1NL4.3
acetylated tubulin to total tubulin in mock transfected cells was set to 100% and relative
signiﬁcance of the results was analyzed by the Student's t-test (⁎=pb0.05).CD4 and infection of HeLaP4 cells is possible. HeLaP4 and 293T cells
were transfected with the proviral constructs and the levels of tubulin
and acetylated tubulin determined (Fig. 1A). As Fig. 1B shows the
transfection of HIV-1NL4.3 resulted in a slight increase of acetylated
tubulin in HeLaP4 cells (115.4±10.5%) which correlates with the
ﬁndings of Valenzuela-Fernandez et al. (Valenzuela-Fernandez et al.,
2005). NL4.3 gp120 binding to neighbouring HeLaP4 cells induces an
increase in acetylated tubulin. For HIV-1NL-A1(CD4−) expressed in
HeLaP4 cells no change in acetylated tubulin was expected since
gp120 expressed in transfected cells cannot bind CD4 on neighbouring
cells to induce a higher level of acetylated tubulin. However, the
expression of HIV-1NL-A1(CD4−) resulted in a signiﬁcant reduction of
acetylated tubulin (54.2±4.4% relative to non-transfected cells). This
substantial reduction was not observed for the expression of HIV-
1NLΔCT in HeLaP4 cells (97.5±1.5%) indicating the cytoplasmic tail of
gp41 in the modulation of tubulin acetylation.
In order to avoid interference of gp120/CD4-induced changes in
acetylated tubulin, transfected 293T cells were also analyzed. For both
HIV-1NL4.3 and HIV-1NL-A1(CD4−) a signiﬁcant reduction in acetylated
tubulin was detected (62.8±12.3% and 60.7±10.5%, respectively). This
reduction however was not observed when the construct with a
deleted cytoplasmic was transfected. HIV-1NLΔCT expression did not
affect the level of acetylated tubulin in 293T cells (102.6±8.9%).
Together these results indicated that the cytoplasmic tail expressed in
HeLa and 293T cells down-modulates acetylated tubulin and thus has
the opposite effect to gp120 binding CD4prior to infection as described
by Valenzuela-Fernandez et al. (Valenzuela-Fernandez et al., 2005).
Expression and localization of the cytoplasmic tail constructs
In order to study the role of cytoplasmic tails in HIV target cells
different cytoplasmic tail-expressing constructs (envCT) were gener-
ated (Fig. 2). The control construct consisting only of themyc- and HA-
tags and the transmembrane domain (TMD) of the platelet derivedral constructs. A) Western blot analysis of total tubulin and acetylated tubulin 48 h after
-A1(D4−) and HIV-1NLΔCT. B) Quantiﬁcation of Western blot results obtained. The ratio of
changes of this ratio due to the expression of the proviral constructs calculated. The
Fig. 2. Localization of cytoplasmic tail constructs. A) Schematic depiction of the generated cytoplasmic tail constructs. All constructs contain an extracellular HA- andmyc-tag at their
N-terminus. The transmembrane domain (TMD) was derived from the platelet derived growth factor receptor (PDGFR). The cytoplasmic tails were cloned fromHIV-1, HIV-2 andMLV
envelope encoding vectors and the full-length constructs (HIV-1/ﬂ; HIV-2/ﬂ) contain the lentiviral lytic peptides 1 and 2 and the leucine zipper domain (LLP1, LLP2, LZ, respectively).
Both endocytosis signals (YxxΦ and LL) are present in these constructs as depicted in the overview. The truncated versions HIV-1/tr and HIV-2/tr lack LLP1, LLP2, LZ and the dileucine
dependent endocytosis signal located in that region (LL). B) Localization of the cytoplasmic tail constructs in transiently transfected HeLaP4 cells. Cells were transfected with the
constructs and stained for confocal microscopy analysis 48 h post transfection.
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(anchor) localizes clearly to the plasma membrane. The full-length
cytoplasmic tails of HIV-1 (HIV-1/ﬂ) and HIV-2 (HIV-2/ﬂ) localize
mainly to the plasma membrane but can also be found in endosomal
vesicles. The truncated versions of both tail constructs (HIV-1/tr and
HIV-2/tr) show a more pronounced localization to the plasma
membrane due to the loss of the dileucine based endocytosis signal
located in the C-terminus of cytoplasmic tail (Berlioz-Torrent et al.,
1999; Bowers et al., 2000; Bultmann et al., 2001; Sauter et al., 1996;
Wyss et al., 2001). In addition, a ‘soluble’ (no TMD) truncated HIV-2
tail (HIV-2/sol) was generated and analyzed. HIV-2/sol localizes
predominantly in the cytoplasm. Furthermore, the short cytoplasmic
tail of the Moloney Leukemia Virus (MLV-CT) was expressed from a
plasmid encoding the HA-/myc-tag and the PDGFR transmembrane
domain. This mini-protein shows a pronounced plasma membrane
association similar to that of the control construct (anchor) and the
shortened tails of HIV-1 and HIV-2 (HIV-1/tr and HIV-2/tr).
Expression of cytoplasmic tail constructs in HeLaP4 cells reduces
acetylated tubulin and interferes with virus–cell fusion
HeLaP4 cells were transfected with the described cytoplasmic tail
constructs and analyzed for the expression of tubulin and the amountof acetylated tubulin. As Fig. 3A shows all lentiviral derived
cytoplasmic tail constructs reduced the level of acetylated tubulin
signiﬁcantly (HIV-1/ﬂ: 21.6±1%; HIV-1/tr: 27.4±1.1%; HIV-2/ﬂ: 25.3±
5.8%; HIV-2/tr: 47.5±5.9% relative to non-transfected cells). The
soluble construct (HIV-2/sol) showed a less pronounced effect
compared to the other cytoplasmic tail constructs but still reduced
the level of acetylated tubulin by 51.3±5.8%. The anchor construct
used as negative control showed no signiﬁcant effect on the amount of
acetylated tubulin as did the MLV-CT construct (anchor 89.6±19.3%
and MLV-CT 72.7±12.7).
To conﬁrm that the cells expressing the cytoplasmic tail constructs
are those containing less acetylated tubulin, individual transfected or
mock transfected cells were analyzed. In Fig. 4 representative pictures
of transfected HeLaP4 cells are shown. HeLaP4 cells expressing the
construct HIV-2/tr (green) showed a marked reduction of acetylated
tubulin (red) compared with non-transfected cells (8.3±1.2%). In
contrast, transfection of the anchor construct did not affect acetylated
tubulin levels (Fig. 4C).
Next, the fusion efﬁciency of virions pseudotyped with different
viral envelope proteins with HeLaP4 cells expressing the cytoplasmic
tail constructs was analyzed. Pseudotyped virions carrying the
envelope protein of HIV-1NL4.3, MLV (amphotroph) or VSV-G together
with the Blam-vpr fusion protein were generated (Fig. 3B). Mock
Fig. 3. Changes in acetylation of tubulin and virus–cell fusion upon expression of HIV cytoplasmic tail constructs. A) HeLaP4 were transfected with the cytoplasmic tail constructs
indicated and analyzed by Western blot for tubulin and acetylated tubulin. Changes relative to mock transfected cells were calculated. B) HeLaP4 cells were transiently transfected
with the respective cytoplasmic tail construct and infected with VSV-G, NL4.3, or MLV envelope pseudotyped virions. 24 h after transfection a virus–cell fusion assay was performed
and changes in fusion relative to mock transfected cells analyzed. The results of three independent experiments are shown (error bars represent the standard deviation). The
signiﬁcance of the results was analyzed by the Student's t-test (⁎=pb0.05; ⁎⁎=pb0.001).
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cells was set to 100% for normalization. The anchor construct used as a
negative control showed no effect irrespective of the pseudotyped
virion assayed, whereas all envCT-constructs derived from HIV-1 and
HIV-2 (HIV-1/ﬂ and HIV-1/tr; HIV-2/ﬂ and HIV-2/tr) signiﬁcantly
reduced viral fusion of NL4.3 envelope and MLV envelope pseudo-
typed virions. The reduction in fusion efﬁciency was slightly more
pronounced for the HIV-2 constructs (HIV-2/ﬂ: 47.9±9.6%; HIV-2/tr:
53.3±5.4% relative to non-transfected cells) compared to the HIV-1
constructs (HIV-1/ﬂ: 59.7±5.2%; HIV-1/tr 53.4±2.6% relative to non-
transfected cells). Cells expressing the ‘soluble’ HIV-2 tail construct
(HIV-2/sol) showed a reduction of fusion comparable to that of the
plasma membrane bound construct HIV-2/tr (45.2±16.6%). Similar
results were obtained for the MLV–cell fusion assay. Interestingly,
expression of the MLV cytoplasmic tail did not interfere with virus–
cell fusion for NL4.3 and MLV envelope pseudotyped virions. None of
the envCT-constructs conferred a reduction in virus–cell fusion for
VSV-G pseudotyped virions. These results conﬁrm the correlation
between acetylated tubulin and virus infection as observed by
Valenzuela-Fernandez et al. (Valenzuela-Fernandez et al., 2005) and
identiﬁes virus–cell fusion at the plasma membrane as the main step
at which modulation of acetylated tubulin interferes with HIV andMLV infection. Only the lentiviral cytoplasmic tails modulate the level
of tubulin acetylation and restrict retrovirus–cell fusion but not VSV-G
mediated virus–cell fusion. In addition, the domain necessary for the
inhibition of fusion was identiﬁed and is located in the membrane
proximal part of gp41-CT.
Identiﬁcation of cytoplasmic tail motifs conferring reduced levels of
acetylated tubulin and reduced virus–cell fusion
In order to identify the speciﬁc motifs required to modulate
acetylated tubulin and thus effect virus–cell fusion, alanine mutations
were introduced along the 45 amino acids of the cytoplasmic tail for
construct HIV-2/tr. Fig. 5A depicts the sequence and the location of the
alanine mutations for the mutant constructs mut1 to mut8 which
were generated by site-directed mutagenesis. Localisation of those
envCT variants did not differ from the localisation of HIV-2/tr with the
exception of mut8 showing a cytoplasmic localisation similar to HIV-
2/sol (Fig. 5B, see Fig. 2 for comparison). First, HelaP4 cells were
transfected with these mutant constructs and changes in acetylated
tubulin compared to the parental construct HIV-2/tr (Fig. 5C) were
determined byWestern blot. The ﬁrst threemutant constructs contain
alanine changes close to the tyrosine-based endocytosis signal YXXΦ,
Fig. 4. Single cell analysis of HIV-2/tr transfected HeLaP4 cells for acetylated tubulin. HeLaP4 cells were transfected with the HIV-2 truncated cytoplasmic tail (A) and the anchor
construct (B) as described above. 48 h post transfection cells were stained for the tail construct (FITC-anti-HA), acetylated tubulin (anti-acetylated-tubulin/anti-mouse-Alexa568) and
total tubulin (anti-tubulin/anti-mouse-Alexa568) and analyzed using a Nikon CiS1 confocal microscope. C) Pixel intensity for stained tubulin and acetylated tubulin signals was
determined for 30 cells per construct and experiment. ImageJ software was used as described in Materials and methods. The results of three independent experiments are
summarized and error bars depict the standard deviation.
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10.1%) did reduce the level of acetylated tubulin signiﬁcantly, mut2
(100.9%±14.7%) and mut3 (82.3±26.6%) had lost the capability to
reduce acetylated tubulin in transfected HeLaP4 cells. For construct
mut4 (64.4%±4.7%), its expression in HelaP4 cells reduced acetylated
tubulin as strongly as the parental construct HIV-2/tr (47.5±5.9%)
whereas the mutations in constructs mut5 to mut8 all abrogated the
phenotype to different extents (mut5: 93.7%±15.9%, mut6: 105.2±
17.1%, mut7: 72.0%±21.5%, mut8: 108.9%±26.8%). These ﬁndings
indicate that there are three potential motifs in the membrane prox-
imal region of the gp41 cytoplasmic domain which are of importance
for the down modulation of acetylated tubulin.
Next, changes in virus–cell fusion were analyzed using a subset of
the mutant constructs (mut1, mut2, mut6 and mut8). Transfected
HeLaP4 cells were infected with NL4.3 or VSV-G envelope pseudo-
typed, Blam-vpr carrying virions and a virus–cell fusion assay was
performed. The results obtained reﬂect those of the Western blot
assays to detect changes in acetylated tubulin. While mut1 reduces
virus–cell fusion to 61.2±11.6%, the three mutants abrogating the
acetylation phenotype also lost the capability to reduce virus–cell
fusion (mut2: 98.5±13.2%, mut6: 97.9±15.2% and mut8: 95.8±12%)
(Fig. 5D). Again a strong correlation between levels of acetylated
tubulin and virus–cell fusionwas observed, suggesting the membrane
proximal domain of the gp41 cytoplasmic domain contains three
motifs capable of interfering with virus–cell fusion.
T-cells stably expressing HIV-2/tr show reduced susceptibility to HIV-1
replication
To include a more relevant target cell into our study we stably
transduced the T cell line PM1 and selected for the expression of HIV-
2/tr and the anchor construct as control cells (PM1/anchor, PM1/HIV-2/tr). A cell viability assay was performed and the expression levels of
CD4 and CXCR4 determined. Both cell lines showed similar growth
kinetics and expression levels for both CD4 and CXCR4 (data not
shown). The anchor and HIV-2/tr envCT-constructs localized to the
plasma membrane of PM1 cells. Next, the PM1 cells were analyzed for
the expression of acetylated tubulin (Fig. 6A). The HIV-2/tr expressing
T-cells showa highly signiﬁcant reduction of acetylated tubulin (64.8±
12.4%) compared with PM1/anchor cells and the parental PM1 cells,
indicating that the envCT-construct interferes with post-translational
modiﬁcations of tubulin not only in HeLaP4 cells but also human
lymphocytes. Moreover, a reduced level of acetylated tubulin can be
tolerated in T-cells. In Fig. 6B the effect of the cytoplasmic tail
constructs on viral replication of HIV-1NL4.3 is depicted. While PM1
cells expressing the anchor construct allow HIV-1 replication to a
similar extent as the parental PM1 cells, the PM1/HIV-2/tr cells show a
reduced replication kinetic (2–3 fold less p24 at days 16 to 25 post
infection). Thus, the expression of the cytoplasmic tail in T-cells does
not affect cell viability but reduces the level of acetylated tubulin and
thus HIV-1 replication.
Modulation of acetylated tubulin levels independent of HIV derived
constructs
Themodulation of acetylated tubulin levels in cells can be achieved
by over expression of proteins involved in the regulation of
microtubule stability as well as by using compounds known to
interfere with tubulin deacetylation. As previously described, the
histone-deacetylase HDAC6 is a regulator of tubulin acetylation and
itself is regulated through a RhoA dependent pathway (Destaing et al.,
2005). In order to study the effect of over expression of HDAC6 and
RhoV14, a constitutively active form of RhoA, HeLaP4 cells were
transfected and quantitative Western blots and virus–cell fusion
Fig. 5. Identiﬁcation of cytoplasmic tail motifs interfering with tubulin acetylation and virus–cell fusion. A) Schematic depiction of the HIV-2 truncated construct and amino acid
sequence of the cytoplasmic tail. Constructs mut1 to mut8 encode double alanine residues at the positions indicated. B) Localization of the mutant cytoplasmic tail constructs mut1,
mut2, mut6 and mut8 in transiently transfected HeLaP4 cells. Cells were transfected with the constructs and stained for confocal microscopy analysis 48 h post transfection.
C) HeLaP4 cells were transfectedwith HIV-2/tr and themutant constructs. Cells were lysed and analyzed byWestern blot and relative changes in the ratio of acetylated tubulin to total
tubulin calculated. D) HeLaP4 cells were transfected with the mutant constructs and 24 h after transfection a virus–cell fusion assay was performed. Changes in virus–cell fusion
relative to mock transfected cells were calculated. The results of three independent experiments are shown. Error bars represent the standard deviation. Signiﬁcance of the
experiments was analyzed by the Student's t-test. (⁎=pb0.05; ⁎⁎=pb0.001).
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resulted in a signiﬁcant reduction of acetylated tubulin (49.4±4.9%
and 9.4±1.5%, respectively) (Fig. 7A, upper panel). As observed after
expression of the HIV envCT-constructs, decreased levels of acetylated
tubulin resulted in reduced virus–cell fusion for NL4.3 (RhoV14: 49.2±
8.4%, HDAC6: 49.8±1.7%) and MLV envelope pseudotyped virions
(RhoV14: 40.5±1.5%, HDAC6: 53.0±3.9%) but not for VSV-G pseudo-
typed virions (Fig. 7B, upper panel). However, the 10-fold reduction in
acetylated tubulin after HDAC6 transfection yielded only a maximum
2-fold reduction in virus–cell fusion. Incubation of HeLaP4 cells with
tubacin and TSA resulted in a 11.7-fold (tubacin) and 4.1-fold (TSA)
increase in acetylated tubulin, correlating with increased infection as
measured by a single cell infection assay using NL4.3 envelope
pseudotyped virions (224.4±53.4% and 202.2±54.9%, respectively,
Figs. 7A and B, lower panel). Again, although an 11.7-fold increase of
acetylated tubulin could be detected, a maximal 2-fold increase in
virus–cell fusion was observed.
Discussion
Host cell cytoskeletal structures present a physical barrier to
viruses during cell entry. For human retroviruses the plasma
membrane constitutes the predominant site of fusion, whereas other
viruses such as vesicular stomatitis virus (VSV) exploit the endosomal
machinery for efﬁcient fusion (Fackler and Krausslich, 2006; Marsh
and Helenius, 2006). Surprisingly little is known about themechanismby which viruses such as HIV use cytoskeletal dynamics to facilitate
virus–cell fusion. Recently, Valenzuela-Fernandez and colleagues
described the role of the histone-deacetylase type 6 (HDAC6) in
modulatingmicrotubule stability through the deacetylation of tubulin.
The authors showed reduced infection and cell–cell fusion after
overexpression of HDAC6 in HIV target cells. Furthermore, they
demonstrated that soluble gp120 induces higher levels of acetylated
tubulin via binding to CD4 suggesting that an increased level of
acetylated tubulin is advantageous to virus infection (Valenzuela-
Fernandez et al., 2005).
Using a CD4-binding deﬁcient proviral plasmid and a plasmid
encoding for an envelope protein lacking the cytoplasmic tail of gp41
we conﬁrmed that gp120/CD4 interaction is indeed required to
increase the level of acetylated tubulin but more importantly, that
the cytoplasmic tail is responsible for the reduction of acetylated
tubulin in transfected cells (Fig. 1). To study this newly observed
phenotype in more detail, several mini-proteins were constructed
using a membrane anchor encoding plasmid containing epitope
tags at the N-terminal end. All HIV derived envCT-constructs led to
the reduction of acetylated tubulin in HeLaP4 cells whereas the
MLV cytoplasmic tail encoding construct did not interfere with
the post-translational modiﬁcation of tubulin (Figs. 2 and 3). This
indicates a lentiviral or human cell speciﬁc mechanism as the same
results were obtained using 293T cells (data not shown). Single cell
analyses conﬁrmed that the observed reduction in acetylated tubulin
is dependent on the expression of the envCT-constructs.
Fig. 6. Effects of the cytoplasmic tail construct HIV-2/tr stably expressed in the T-cell
line PM1. A) PM1 cells were lysed and analyzed by Western blot for total tubulin
and acetylated tubulin. Three independent experiments are summarized. Error bars
show the standard deviation. The signiﬁcance of the values was evaluated by the
Student's t-test (⁎⁎=pb0.001). B) PM1 cells were infected with a replication competent
HIV-1NL4.3 (MOI=0.1) and virus replication monitored until day 25. One representative
result out of three independent challenge experiments is shown.
Fig. 7. Interference with the tubulin modiﬁcations and effect on virus–cell fusion and single-
RhoV14 or treated with the inhibitors tubacin or TSA for 1 h. Changes in the ratio of acetylated
used forWestern blotting. The upper panel shows the results for the transfections, the lower p
either transiently transfected with HDAC6-GPP or RhoV14 24 h prior to infection with NL4.3
The transfected cells were analyzed using the virus–cell fusion assay while the cells treated w
mean values of three independent experiments and standard deviations are depicted by th
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line PM1 also revealed a signiﬁcant reduction in the level of acetylated
tubulin, supporting the notion that its effect on cytoskeletal structures
is an important feature of lentiviral cytoplasmic tails expressed in HIV
target cells. Interestingly, the growth kinetics of the stable T-cell line
did not change due to the expression of the cytoplasmic tail construct
or the reduced level of acetylated tubulin (data not shown).
Our studies using a number of truncated and soluble forms of the
envCT-constructs clearly demonstrate that the observed reduction in
acetylated tubulin is independent of lentivirus-lytic-peptide domains
(LLP1 to LLP3) and notmediated through plasma-membrane localization.
The recently described interaction domain of gp41 CT with the
transcription factor luman (Blot et al., 2006) is partly present in the
truncated cytoplasmic tail construct HIV-1/tr and this construct confers a
reduction in fusion efﬁciency of 53.4±2.6% relative to mock transfected
cells. However, luman localizes to the ER or, upon activation, to the
nucleus and thus is unlikely to be responsible for the observedphenotype.
To further delineate the motif/s responsible for the reduction of
acetylated tubulin a series of alanine mutants was tested and three
regions in the truncated HIV-2 cytoplasmic tail were identiﬁed.
Mutations close to the YxxΦ endocytosis signal abrogated the
phenotype (mut2 and mut3) as did those in the c-terminal end
(amino acid 21 to 45 of the cytoplasmic tail in HIV-2/tr) of the
truncated cytoplasmic tail (mut5 to mut8). It has been described that
the YxxΦ motif is needed to mediate clathrin-dependent endocytosis
of the envelope protein via interaction with AP-1 and AP-2 (Byland
et al., 2007). The second motif identiﬁed corresponds to a more
variable region of both HIV-1 and HIV-2 cytoplasmic tails. Interest-
ingly, amino acids 30 to 35 in HIV-2 (EETEED) are highly conserved
while the ﬂanking sequences are responsible for the high variability
observed between HIV-2 subtypes A and B. The same is true for HIV-1
(amino acids 26–31: EEEGGE) whereas this motif is not present in the
MLV cytoplasmic tail. The studied alanine mutations in the HIV-2/tr
construct do not affect the EETEED motif but introduce changes in theround infection. A) HeLaP4 cells were either transiently transfected with HDAC6-GFP or
tubulin to total tubulinwere calculated fromWestern blot results. Cells were lysed and
anel shows the effect of the inhibitors on the acetylation of tubulin. B) HeLaP4 cells were
envelope pseudotyped particles or incubated with tubacin or TSA 1 h prior to infection.
ith the inhibitors were analyzed with a single-round-infection assay. Both panels show
e error bars. Signiﬁcance was evaluated by Student's t-test as described in A.
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Alamos database. It is tempting to speculate that these changes
interfere with the accessibility of the EETEED motif for a yet to be
identiﬁed cellular factor. The third identiﬁed motif located to the very
end of the truncated tail (mut8). Changing the two terminal serine
residues to alanine abrogates the effect on acetylated tubulin and
virus–cell fusion although this construct locates in the cytoplasma as
does HIV-2/sol. Future experiments using HIV-2/tr and one of the
mutant constructs described will identify cellular factors involved and
allow delineation of the mechanism responsible for changes in
acetylated tubulin levels and virus–cell fusion.
Since the level of acetylated tubulin can modulate HIV infection,
we studied the effect these envCT-constructs have on virus–cell
fusion. We demonstrate that virus–cell fusion is impaired in cells
expressing HIV-1 and HIV-2 cytoplasmic tails. This reductionwas seen
for HIV-1 and MLV envelope pseudotyped particles but not for VSV-G
pseudotyped particles on HeLaP4 cells and for HIV replication in the
transduced T-cell line PM1 (Figs. 3 and 6). Our data on the
susceptibility of T-cells stably expressing the cytoplasmic tail
construct HIV-2/tr clearly show, that the envCT-mediated effect can
be observed not only in HeLaP4 cells but also in more relevant HIV
target cells (Fig. 6). The expression of cytoplasmic tails in HeLaP4 cells
speciﬁcally interferes with virus fusion at the plasma membrane and
not from endosomal membranes. Remarkably, the effect is speciﬁc for
lentiviral tails because expression of a heterologous MLV cytoplasmic
tail had no effect on viral fusion. The endosomal pathway (VSV-G
mediated fusion) is not affected. It has been shown that HIV and MLV
envelope mediated infection occurs via endosomal and/or caveolae
uptake (Beer et al., 2005; Daecke et al., 2005) in addition to fusion at
the plasma membrane. Whether the 2–3 fold reduction described
here reﬂects fusion from endosomal membranes or the presence of
another pathway independent of microtubule stability needs to be
deﬁned. The screening system described here will be useful to address
this question in the future.
The reduction in acetylated tubulin after transfection of envCT-
constructs is comparable to that observed when a constitutively active
form of RhoA (RhoV14) is over expressed in cells (Hubbert et al., 2002;
Matsuyama et al., 2002; Zhang et al., 2003). Again, our results conﬁrm
the ﬁndings by Valenzuela-Fernandez et al. (Valenzuela-Fernandez
et al., 2005) andWang et al. (Wang et al., 2000) and identify the fusion
step as the main target for inhibition of infection through the
modulation of acetylated tubulin levels in cells (Fig. 7). There are
conﬂicting data regarding the role of RhoA on HIV-1 replication. Del
Real et al. described inhibition of cell–cell fusion in the presence of a
dominant negative form of RhoA (del Real et al., 2004), whereasWang
et al. showed that activation of RhoA inhibited HIV-1 infection via a
pathway distinct from its effects on actin stress ﬁber formation (Wang
et al., 2000). The latter results support our suggestion of a RhoA/mDia/
HDAC6 pathway, however more experiments are needed to clarify the
role of RhoA. Using small molecules to inhibit HDAC6 in HIV target
cells we observed a strong increase in acetylated tubulin but only a 2
fold increase in viral infection as measured using a single-round
infection assay. Over expression of HDAC6 resulted in a 10 fold
reduction of acetylated tubulin but only a 2 fold decrease in virus–cell
fusion. This indicates that the modulation of acetylated tubulin only
achieves a 2 fold reduction in infection. However, interfering with the
microtubule stability due to tubacin treatment or HDAC over
expression could have resulted in less viable cells in our assay system
thus overestimating the effect on acetylated tubulin. Further studies
with careful titration of tubacin or similar drugs known to interfere
with microtubule stability will give further insight into the achievable
magnitude of inhibition of virus–cell fusion.
Although the reduction in fusion efﬁciency is more pronounced in
cytoplasmic tail transfected HeLaP4 cells compared with the reduced
replication kinetic in PM1/HIV-2/tr cells, both results, argue for
tubulin or post-translational modiﬁcations of tubulin, such asacetylation, being novel cellular targets for prevention of HIV infection
at a very early stage. Compounds that stabilize or destabilize
microtubules have been identiﬁed and are being evaluated in clinical
trials as anti cancer drugs (Hideshima et al., 2005; Mani et al., 2004).
Whether those compounds exert potent anti-viral activity through
interference with the HIV–cell fusion step remains to be tested.
Materials and methods
Antibodies
The following antibodies were used for this study: monoclonal
mouse anti α-tubulin antibody (clone DM-1A, Santa Cruz, Germany),
mouse anti-acetylated tubulin antibody (clone 6-11B-1, Sigma, Ger-
many), monoclonal FITC-conjugated anti-HA antibody (Santa Cruz,
Germany), monoclonal anti-HA antibody (Roche, Germany), polyclonal
Alexa568-conjugated anti-mouse antibody (Molecular Probes, Ger-
many), polyclonal goat anti-mouse PO (Jackson, Great Britain).
Plasmids and cell lines
Mini proteins containing an HA- and myc-tag and the transmem-
brane domain (TMD) of platelet derived growth factor receptor
(PDGFR) derived from pDisplay (Invitrogen, Germany) and the cyto-
plasmic domains of HIV-1NL4.3 (U26942.1; full-length: aa687–aa841;
truncated: aa687–aa731), HIV-2CBL23 (full-length: aa697–aa859:
LRKGYRPVFSSPPGYLQQIHIHKDWEQRAREETEEDVGNNVGDSSWPWPIRY-
IHFLIHQLIRLLTGLYNICRNLLSRISLTLRPVFQSLQRALTAIRDW-
LRTDAAYLQRIGRGILAVPRRIRQGAEIALL; truncated: aa697–aa741:
LRKGYRPVFSSPPGYLQQIHIHKDWEQRAR EETEEDVGNNVGDS) and MLV
(J02255, aa626–aa658) were expressed from the TO/4 vector (Invitrogen,
Germany). The HIV-2 soluble proteinwas generated by deletion of the
transmembrane domain of pDisplay. Point mutations to identify
motifs in HIV-2/tr (mut1 to mut8) were introduced using the
QuikChange XL site-directed mutagenesis kit (Stratagene, Germany)
and conﬁrmed by sequence analysis. The vectors pNL-3K, pA1-CD4-
and pNL-ΔCT have been described (Dittmar et al., 1999; Strebel et al.,
1987; Wilk et al., 1992). HIV-1NL-A1(CD4−) carries a 12 amino acid
deletion in the gp120 CD4 binding region preventing CD4 binding and
gp120/CD4 mediated signalling due to conformational changes of the
outer envelope. HIV-1NLΔCT encoded a premature stop codon at amino
acid 712 in the envelope open reading frame resulting in the
truncation of the gp41 cytoplasmic domain (Wilk et al., 1992).
pRhoV14 (Muller et al., 1997) and pLZR-hHDAC6 (Valenzuela-
Fernandez et al., 2005) were previously described.
HeLaP4, a HeLa derivative expressing CD4, and 293T cells were
grown in DMEM supplemented with 10% FCS, 100 U/ml penicillin/
streptomycin and 4 mM glutamate. PM1 cells were grown in RPMI
1640 supplemented with 10% FCS and 100 U/ml pen/strep. PM1 cells
stably expressing the anchor or the HIV-2 truncated tail were
generated through transduction with retroviral vectors encoding for
the anchor construct or HIV-2/tr together with eGFP and sorting for
eGFP expressing cells.
Western blot
Mock transfected HelaP4 cells and HelaP4 cells transfected with
the CT-constructs were lysed 48 h post transfection. Cell lysates were
subsequently loaded on a 14% SDS-polyacrylamide gel, transferred and
tubulin and acetylated tubulin were detected using appropriate
antibodies. For visualization a goat anti-mouse-antibody conjugated
to horseradish peroxidase was used in a 1:5000 dilution. The ﬁlms
were quantiﬁed using ‘quantity one’ software and the ratios of
acetylated tubulin to total tubulin were calculated for all samples. The
ratio of acetylated tubulin to total tubulin for non-transfected cells
was set to 100%. PM1 cells were assayed in the same way.
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293T cells were transfected with pCMVΔ8.74, pHRCMV-GFP (Naldini
et al., 1996), Blam-vpr1 and one of the envelope protein-encoding
plasmids MP11-NL, M3-VSV-G or pAmpho/Env with polyethylenimine
(1mg/ml). 72hpost transfectionpseudotypedvirionswereharvestedand
puriﬁed by ultracentrifugation through a 20% sucrose cushion. HeLaP4
cells were seeded at 1×104 per well in 24-well plates on coverslips and
transfected with the plasmids encoding the cytoplasmic tailconstructs.
24hpost transfection cellswere infectedwith thepseudotypedvirions for
4 h, and subsequently stained with CCF2 as described (Cavrois et al.,
2002). Virus–cell fusion was analyzed using either an Olympus IX70
microscope or a BD-LSR1-FACS. For each independent microscopic
experiment approximately 800 cells were counted while for the
FACS based assays 20,000 cells per experiment were analyzed.
Single round infection assay
HeLaP4 cells were used for single-round infections using pseudo-
typed particles based on the TN7stopp vector combinedwith theMP11-
NL vector as described previously (Lohrengel et al., 2005). Cells were
lysed 2 days post infection and Renilla luciferase activity was
measured using the Renilla Assay system (Promega, Germany).
Microscopy and FACS analysis
HeLaP4 cells were transfected with the plasmids encoding the
cytoplasmic tail constructs and stained with a FITC-conjugated anti-
HA-antibody to visualize the cellular localization of the proteins. To
analyze the inﬂuence of the tails on acetylated tubulin at a single cell
level the cells were double stained with FITC-conjugated anti-HA-
antibody and anti-α-tubulin/acetylated tubulin antibody. The latter
was visualized by a secondary anti-mouse-Alexa568 antibody. The
cells were analyzed using a C1Si confocal microscope (Nikon). To
quantify the amount of tubulin and acetylated tubulin in single cells,
image stacks of 30 transfected and 30 non-transfected cells per assay
were taken and the pixel intensity of each slide measured using
ImageJ software (NIH). The mean protein expression in 30 cells was
determined for non-transfected and transfected cells and the amount
of tubulin/acetylated tubulin in non-transfected cells was set to 100%.
Replication assay
Parental PM1 cells or stably transduced PM1 cells (1×106) were
infected with HIV-1NL4.3 derived from transfections of 293T cells at an
MOI of 0.01. After 4 h the cells were washed three times with PBS. At
days 2 to 25 post infection p24 in the medium was measured by a
standard ELISA-assay (Dittmar et al., 2001).
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